Want to see IN:DCAL full AI Analyst Report?
DCAL Stock Chart & Stats
₹255.15
-₹14.00(-4.80%)
At close: 4:00 PM EST
₹255.15
-₹14.00(-4.80%)
Day’s Range― - ―
52-Week Range₹129.00 - ₹321.15
Previous CloseN/A
Volume578.20K
Average Volume (3M)13.55K
Market Cap
₹29.48B
Enterprise Value₹47.16B
Total Cash (Recent Filing)₹5.32B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)30.2
Beta1.20
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.65
Shares Outstanding156,783,100
10 Day Avg. Volume9,637
30 Day Avg. Volume13,551
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.30
Price to Sales (P/S)0.69
P/FCF Ratio26.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Business Model / CDMO & Specialty ChemicalsThe firm's dual model—CDMO/CRAMS plus in-house specialty chemicals—provides diversified, service-driven revenue streams tied to development and commercial production for life‑science clients. This structural positioning supports recurring project work and long-term client relationships, helping revenue durability across cycles.
Revenue Growth TrendSteady top-line expansion with a recent re-acceleration indicates improving market traction and successful scaling of projects. Persistent revenue growth supports investment in capacity and R&D, improving the company's ability to win larger, longer-term CDMO contracts and smooth revenue volatility over the medium term.
Operating Cash Flow ResilienceConsistent positive operating cash flow underpins the business's ability to fund working capital and incremental capex without constant external financing. Over 2–6 months this provides durable financial flexibility to execute contracts, maintain manufacturing capacity, and service rising debt, improving operational resilience.
Bears Say
Profitability VolatilityLarge swings between loss years and profitable years indicate unstable margins and uneven earnings quality. This volatility complicates forecasting, weakens confidence in recurring profitability, and raises execution risk on scaling operations and sustaining margins as contract mix and pricing shift.
Rising Debt And Weak ROEAn upward debt trajectory combined with weak or negative ROE suggests capital is not consistently generating adequate returns. Higher leverage raises financing costs and reduces strategic flexibility, constraining reinvestment or pace of capacity expansion if earnings do not stabilise.
Uneven Free Cash Flow ConversionIrregular free cash flow conversion limits the firm's ability to self-fund growth, pay down debt, or return capital consistently. Periods of negative FCF highlight sensitivity to capex and working capital timing, increasing the need for careful liquidity management during multi-year contract cycles.
Dishman Carbogen Amcis Ltd. News
DCAL FAQ
What was Dishman Carbogen Amcis Ltd.’s price range in the past 12 months?
Dishman Carbogen Amcis Ltd. lowest stock price was ₹129.00 and its highest was ₹321.15 in the past 12 months.
What is Dishman Carbogen Amcis Ltd.’s market cap?
Dishman Carbogen Amcis Ltd.’s market cap is ₹29.48B.
When is Dishman Carbogen Amcis Ltd.’s upcoming earnings report date?
Dishman Carbogen Amcis Ltd.’s upcoming earnings report date is Aug 12, 2026 which is in 39 days.
How were Dishman Carbogen Amcis Ltd.’s earnings last quarter?
Dishman Carbogen Amcis Ltd. released its earnings results on May 19, 2026. The company reported ₹1.39 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.39.
Is Dishman Carbogen Amcis Ltd. overvalued?
According to Wall Street analysts Dishman Carbogen Amcis Ltd.’s price is currently Overvalued.
Does Dishman Carbogen Amcis Ltd. pay dividends?
Dishman Carbogen Amcis Ltd. pays a Annually dividend of ₹0.2 which represents an annual dividend yield of N/A. See more information on Dishman Carbogen Amcis Ltd. dividends here
What is Dishman Carbogen Amcis Ltd.’s EPS estimate?
Dishman Carbogen Amcis Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dishman Carbogen Amcis Ltd. have?
Dishman Carbogen Amcis Ltd. has 156,783,100 shares outstanding.
What happened to Dishman Carbogen Amcis Ltd.’s price movement after its last earnings report?
Dishman Carbogen Amcis Ltd. reported an EPS of ₹1.39 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.399%.
Which hedge fund is a major shareholder of Dishman Carbogen Amcis Ltd.?
Currently, no hedge funds are holding shares in IN:DCAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dishman Carbogen Amcis Ltd.
Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited provides specialized contract research and manufacturing solutions to the worldwide pharmaceutical sector. The company operates through two main business segments: Contract Research and Manufacturing Services (CR&MS), and Marketable Molecules. Beyond its core services, it manufactures and distributes an extensive portfolio of products, including bulk drugs, chemical intermediates, various phase transfer catalysts, quaternary ammonium compounds, phosphoranes, wittig reagents, vitamin D derivatives, and fine chemicals. Additionally, its offerings encompass personal care products like hand and body washes, sanitizers, and antiseptics, as well as a range of pharmaceutical and cosmetic formulations, including generic and highly potent active pharmaceutical ingredients. Dishman Carbogen Amcis Limited is a subsidiary of Adimans Technologies LLP.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Jubilant Ingrevia Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―